A new JAMA study found that after Dobbs, commercially insured patients with first-trimester miscarriages in states with trigger abortion bans were less likely to receive medication management and more likely to be managed expectantly.
A new JAMA study found that abortion bans were associated with worse miscarriage care after the Supreme Court’s Dobbs decision, including less medication management and more expectant management for commercially insured patients.
The study, published online May 18, examined management of first-trimester spontaneous abortion, the medical term for miscarriage, among commercially insured individuals in the United States. Researchers compared care before and after Dobbs in states with trigger abortion bans and in comparison states.
According to the study’s key findings, care shifted away from evidence-based management in the states with bans. The changes included a decline in medication treatment and an increase in expectant management, when clinicians monitor the miscarriage and wait for it to resolve on its own.
Oregon Health & Science University, where researchers were based, said the findings show abortion restrictions can affect routine miscarriage treatment, not only access to elective abortion. Science News also independently reported the same results from the JAMA paper.
The findings add to evidence that post-Dobbs abortion restrictions may affect broader reproductive health care. The research did not appear to raise conflicting claims in the sources reviewed, but the study’s policy implications are likely to draw further attention as more reporting and expert reaction emerge.
JAMA’s online publication makes this a fresh research-driven news event rather than a retrospective review, and it points to an immediate question for states with abortion bans: whether miscarriage care is becoming less standardized or less evidence-based under current restrictions.
Revision note
Initial automated publication.